Glass bead-activated clotting time (gb-ACT) for monitoring the anticoagulation effects in elderly patients with high risk of venous thromboembolism (VTE)

References

• Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004 Sep;126(3 Suppl):338S–400S. doi: 10.1378/chest.126.3_suppl.338S
   PubMed Web of Science ®Google Scholar
• Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999 Apr 3;353(9159):1167–1173. doi: 10.1016/S0140-6736(98)10266-0
   PubMed Web of Science ®Google Scholar
• Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg. 2008 May;106(5):1366–1375. doi: 10.1213/ane.0b013e318168b367
   PubMed Web of Science ®Google Scholar
• Hett DA, Walker D, Pilkington SN, et al. Sonoclot analysis. Br J Anaesth. 1995 Dec;75(6):771–776. doi: 10.1093/bja/75.6.771
   PubMed Web of Science ®Google Scholar
• Yang WX, Lai CL, Chen FH, et al. The value of Sonoclot detection technology to guide the clinical medication of the perioperative anticoagulation and antiplatelet therapy in patients with acute myocardial infarction undergoing emergent PCI. Exp Ther Med. 2017 Jun;13(6):2917–2921. doi: 10.3892/etm.2017.4336
   PubMed Web of Science ®Google Scholar
• Miyashita T, Kuro M. Evaluation of platelet function by Sonoclot analysis compared with other hemostatic variables in cardiac surgery. Anesth Analg. 1998 Dec;87(6):1228–1233. doi: 10.1213/00000539-199812000-00002
   PubMed Web of Science ®Google Scholar
• Levy JH, Sniecinski RM. Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years? Anesth Analg. 2010 Oct;111(4):833–835. doi: 10.1213/ANE.0b013e3181f08a80
   PubMed Web of Science ®Google Scholar
• Wang JQ, Shi XB, Yang JG, et al. In vitro anticoagulation monitoring of low-molecular-weight heparin. Chin Med J (Engl). 2009 May 20;122(10):1199–1202.
   PubMed Web of Science ®Google Scholar
• Yamada T, Katori N, Tanaka KA, et al. Impact of Sonoclot hemostasis analysis after cardiopulmonary bypass on postoperative hemorrhage in cardiac surgery. J Anesth. 2007;21(2):148–152. doi: 10.1007/s00540-006-0477-7
   PubMed Web of Science ®Google Scholar
• Rajkumar V, Kumar B, Dutta V, et al. Utility of sonoclot in prediction of postoperative bleeding in pediatric patients undergoing cardiac surgery for congenital cyanotic heart disease: a prospective observational study. J Cardiothorac Vasc Anesth. 2017 Jun;31(3):901–908. doi: 10.1053/j.jvca.2017.02.002
   PubMed Web of Science ®Google Scholar
• Babski DM, Brainard BM, Ralph AG, et al. Sonoclot(R) evaluation of single- and multiple-dose subcutaneous unfractionated heparin therapy in healthy adult dogs. J Vet Intern Med. 2012 May;26(3):631–638. doi: 10.1111/j.1939-1676.2012.00907.x
   PubMed Web of Science ®Google Scholar
• Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):257S–298S. doi: 10.1378/chest.08-0674
   PubMed Web of Science ®Google Scholar
• Weill-Engerer S, Meaume S, Lahlou A, et al. Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc. 2004 Aug;52(8):1299–1304. doi: 10.1111/j.1532-5415.2004.52359.x
   PubMed Web of Science ®Google Scholar
• Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002 May;143(5):753–759. doi: 10.1067/mhj.2002.120774
   PubMed Web of Science ®Google Scholar
• Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy. 2000 Jul;20(7):771–775. doi: 10.1592/phco.20.9.771.35210
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 Oct 30;349(18):1695–1702.
   PubMed Web of Science ®Google Scholar
• Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol. 2003 Jun;43(6):586–590. doi: 10.1177/0091270003253420
   PubMed Web of Science ®Google Scholar
• Mahe I, Gouin-Thibault I, Drouet L, et al. Elderly medical patients treated with prophylactic dosages of enoxaparin - Influence of renal function on anti-Xa activity level. Drugs Aging. 2007;24(1):63–71. doi: 10.2165/00002512-200724010-00005
   PubMed Web of Science ®Google Scholar
• Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost. 1998 Jun;79(6):1162–1165. doi: 10.1055/s-0037-1615034
   PubMed Web of Science ®Google Scholar
• Min J, Wan P, Liu G, et al. Sonoclot signature analysis: a new point-of-care testing method for defining heat stroke-induced coagulopathy. Int J Gen Med. 2021;14:6925–6933. doi: 10.2147/IJGM.S321982
   PubMed Web of Science ®Google Scholar
• Roosendaal LC, van den Ancker W, Wiersema AM, et al. Unfractionated heparin and the activated clotting time in non-cardiac arterial procedures. J Cardiovasc Surg (Torino). 2023 May 31;64(5). doi: 10.23736/S0021-9509.23.12723-6
   PubMed Web of Science ®Google Scholar
• Díaz Gómez E, Del Olmo D S, Corregidor Luna L, et al. Haemorrhagic complications in patients with renal insufficiency during treatment or prophylaxis with dalteparin. Eur J Hosp Pharm. 2022 Jul;29(4):187–191. doi: 10.1136/ejhpharm-2020-002262
   PubMedGoogle Scholar
• Fox KA, Antman EM, Montalescot G, et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007 Jun 12;49(23):2249–2255. doi: 10.1016/j.jacc.2006.12.049
   PubMed Web of Science ®Google Scholar
• Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):454S–45S. doi: 10.1378/chest.08-0658
   PubMed Web of Science ®Google Scholar
• Marshall AM, Trussell TM, Yee AM, et al. Anti-Xa levels in critically ill children receiving enoxaparin for venothromboembolism prophylaxis. Thromb Res. 2021 Jul;203:117–120. doi: 10.1016/j.thromres.2021.04.019
   PubMed Web of Science ®Google Scholar